280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY

71% and 36% of GlofitþR-CHOP-treated pts and 67% and 58% of GlofitþPola-R-CHP-treated pts.Gr 3/4 neutropenia, febrile neutropenia, thrombocytopenia, and anemia occurred in 43%, 14%, 4%, and 23% of pts in the GlofitþR-CHOP cohort, and 58%, 8%, 17%, and 17% of pts in the GlofitþPola-R-CHP cohort, respectively.Cytokine release syndrome occurred in 11% of GlofitþR-CHOP-and 13% of GlofitþPola-R-CHP-treated pts; all were Gr 1/2 (by ASTCT criteria) and resolved; 22.2% of pts received tocilizumab (all in the GlofitþR-CHOP cohort).Infections occurred in 50% of pts in both cohorts (GlofitþR-CHOP: Gr 3/4 [14%], Gr 5 [5%]; GlofitþPola-R-CHP: Gr 3/4 [21%]; no Gr 5 events).No ICANS events were reported after administering Glofit.Median treatment dose intensity was 100% for all components.Conclusion: This analysis of Glofit with R-CHOP or Pola-R-CHP confirmed early promising results with high rates of CMR, durable responses, and manageable safety in pts with 1L DLBCL.The ongoing Phase 3 SKYGLO study (NCT06047080) will further evaluate the efficacy and safety of GlofitþPola-R-CHP versus Pola-R-CHP.